Co-carriage of bla KPC-33 and tmexCD2-toprJ2 on a Transferable Plasmid in an ST15-KL19 Klebsiella pneumoniae Isolate

In the microscopic world of bacteria, survival often depends on a constant arms race against the medicines designed to kill them. When doctors treat serious infections, they rely on powerful antibiotics, but bacteria can evolve defenses that render these drugs useless. Two of the most critical defenses involve different strategies: one involves producing an enzyme that acts like a pair of scissors, snipping apart the chemical structure of a drug before it can work, while the other uses a pump system to actively eject the drug from the cell. For years, scientists have watched these defenses spread, often finding them in different bacteria or on different genetic carriers. The concern arises when these distinct defenses appear together, especially if they hitch a ride on the same mobile genetic vehicle, allowing a single bacterium to become resistant to multiple classes of drugs at once. This scenario creates a significant challenge for modern medicine, as it limits the available tools for treating infections.

Researchers in China recently uncovered a specific instance of this convergence in a strain of Klebsiella pneumoniae, a common cause of hospital-acquired infections. They isolated a bacterium from a patient and discovered it carried two major resistance mechanisms on a single, transferable piece of genetic material. This bacterium, identified as strain 1640, was found to possess a gene that produces a modified version of a drug-cutting enzyme, alongside a gene cluster that encodes a drug-ejecting pump. What made this discovery particularly notable was that both of these resistance tools were located on the same circular ring of DNA, known as a plasmid, which the bacterium could pass on to others. The study confirmed that this plasmid could successfully jump from the original Klebsiella strain to a different type of bacteria, Escherichia coli, in a laboratory setting, transferring the resistance capabilities in the process.

The strain itself, designated as 1640, presented a complex picture when tested against various antibiotics. It proved resistant to a specific combination drug used to treat difficult infections, yet it remained vulnerable to other powerful antibiotics that are often used as a last resort. This mismatch between the genes the bacteria carried and the actual behavior of the bacteria was a key focus of the investigation. The researchers found that the bacterium carried a specific variant of the cutting enzyme, known as KPC-33, which is a modified version of a more common enzyme. This modification allows the bacteria to resist the drug combination that usually stops the standard version. At the same time, the strain carried a gene cluster responsible for a pump system that typically reduces the effectiveness of a drug called tigecycline. However, despite carrying the genes for this pump, the bacterium did not show the expected resistance to tigecycline in the lab tests.

To understand how these genes were arranged, the team mapped the entire genetic blueprint of the bacterium. They found that the cutting enzyme gene and the pump gene cluster were sitting side-by-side on a plasmid that was roughly 146,193 base pairs in length. This plasmid was not just a random collection of genes; it had a specific structure that allowed it to move between bacteria. The researchers compared this plasmid to others found in different bacteria and found that while the main body of the plasmid was very similar to known genetic carriers, the specific regions holding the resistance genes had unique features. The cutting enzyme gene was surrounded by specific genetic elements that differed from those found in other similar plasmids, while the pump gene cluster was highly conserved, meaning it looked very much like versions found in other bacteria.

The team then tested whether this plasmid could actually move from one bacterium to another. They mixed the original strain with a harmless strain of E. coli in a controlled environment. The experiment showed that the plasmid successfully transferred to the E. coli at a measurable rate. Once the E. coli received the plasmid, it became resistant to the same combination drug that the original strain resisted. However, even after receiving the pump genes, the E. coli did not become resistant to tigecycline. This result reinforced the idea that simply having the pump genes does not guarantee resistance; other factors within the bacterium likely influence whether the pump works effectively.

Further analysis placed this strain within a specific family of bacteria known as sequence type 15, which is found globally but is particularly common in China. The researchers compared the genetic makeup of strain 1640 to nearly one hundred other strains from this family. While the core genetic structure of the bacterium was very similar to other Chinese strains, the resistance genes it carried were unique. None of the other strains in the comparison carried the exact same combination of the cutting enzyme variant and the pump gene cluster. This suggests that the strain acquired these specific resistance tools through the movement of genetic material rather than by slowly evolving them over a long period. The study concludes that while the bacterium's resistance profile was complex and not fully predictable from its genes alone, the presence of both major resistance mechanisms on a single, mobile plasmid represents a significant risk. This setup allows for the potential spread of multiple resistance traits simultaneously, highlighting the need for continued monitoring of how these genetic elements move and combine in bacterial populations.